The future of low-density lipoprotein cholesterol lowering therapy: An end to statin exceptionalism?

European Journal of Preventive Cardiology

Volumn 23, Issue 10, 2016, Pages 1062-1064

  Khera, Amit V ^a   Natarajan, Pradeep ^a   Kathiresan, Sekar ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALIROCUMAB; EVOLOCUMAB; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; NIEMANN PICK C1 LIKE 1 PROTEIN; SIMVASTATIN; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); COST EFFECTIVENESS ANALYSIS; DRUG SAFETY; DRUG TOLERABILITY; GENE LOCUS; GENETIC VARIABILITY; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; HEART PROTECTION; HUMAN; HUMAN GENETICS; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; NOTE; PRIORITY JOURNAL; PROTEIN DEGRADATION; RISK REDUCTION;

CHOLESTEROL, HDL; CHOLESTEROL, LDL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA;

EID: 84974588575     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1177/2047487315600818     Document Type: Note

References (7)

1. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015; 372: 2387-2397.
2. Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372: 1489-1499.
3. Sabatine MS, Giugliano RP, Wiviott SD, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372: 1500-1509.
4. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-1278.
5. Voight BF, Peloso GM, Orho-Melander M, et al. Plasma HDL cholesterol and risk of myocardial infarction: A mendelian randomisation study. Lancet 2012; 380: 572-580.
6. Myocardial Infarction Genetics Consortium Investigators. Inactivating mutations in NPC1L1 and protection from coronary heart disease. N Engl J Med 2014; 371: 2072-2082.
7. Swerdlow DI, Preiss D, Kuchenbaecker KB, et al. HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: Evidence from genetic analysis and randomised trials. Lancet 2015; 385: 351-361.